1. Home
  2. ROOT vs SPRY Comparison

ROOT vs SPRY Comparison

Compare ROOT & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Root Inc.

ROOT

Root Inc.

HOLD

Current Price

$57.77

Market Cap

862.0M

Sector

Finance

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.07

Market Cap

823.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROOT
SPRY
Founded
2015
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
862.0M
823.2M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ROOT
SPRY
Price
$57.77
$8.07
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$92.40
$40.00
AVG Volume (30 Days)
270.9K
1.7M
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
28.96
N/A
EPS
2.09
N/A
Revenue
$1,517,100,000.00
$84,278,000.00
Revenue This Year
$11.73
$87.40
Revenue Next Year
$12.80
$81.64
P/E Ratio
$27.67
N/A
Revenue Growth
28.95
N/A
52 Week Low
$40.91
$6.66
52 Week High
$162.99
$18.63

Technical Indicators

Market Signals
Indicator
ROOT
SPRY
Relative Strength Index (RSI) 56.46 49.40
Support Level $55.57 $7.82
Resistance Level $58.03 $8.61
Average True Range (ATR) 3.78 0.55
MACD -0.11 -0.04
Stochastic Oscillator 43.12 42.91

Price Performance

Historical Comparison
ROOT
SPRY

About ROOT Root Inc.

Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: